Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY2886721 in a Capsule
LY2886721 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY2886721 Capsule (water, fasting) | EXPERIMENTAL | Reference formulation. A single oral dose of 70 milligrams (mg) LY2886721 in a capsule given with water and without a meal in one of four periods. |
| LY2886721 ODT (no water, fasting) | EXPERIMENTAL | A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given without water and without a meal in one of four periods. |
| LY2886721 ODT (water, fed) | EXPERIMENTAL | A single oral dose of a 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and after a high-fat breakfast in one of four periods. |
| LY2886721 ODT (water, fasting) | EXPERIMENTAL | A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and without a meal in one of four periods. |
| Name | Type | Description |
|---|---|---|
| LY2886721 in a Capsule | DRUG | Administered orally. |
| LY2886721 in an orally disintegrating tablet (ODT) | DRUG | Administered orally. |
Inclusion Criteria: * Have a body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m\^2), inclusive, at screening * At least 4 participants who are greater than 55 years of age * Male participants: Agree to use a reliable method of birth control and not donate sperm during the study ...
LY2886721 in a is an investigational small molecule developed by Eli Lilly and Company. It was studied in a Phase 1 clinical trial in healthy volunteers. The capsule dosage form was evaluated in a completed study of 26 participants. The specific therapeutic indication for this drug has not been disclosed.
LY2886721 in a is being developed by Eli Lilly and Company, which trades under the ticker symbol LLY. Eli Lilly sponsored the Phase 1 trial of this capsule formulation. The company is responsible for the clinical development of this investigational asset.
LY2886721 in a is in Phase 1 clinical development. It has completed one Phase 1 trial in healthy volunteers. The drug is investigational and has not been approved by the FDA for any indication. Further development status beyond Phase 1 has not been disclosed.
LY2886721 in a has been studied in one clinical trial: NCT01775904, titled A Study of Two Dosage Forms of LY2886721 in Healthy Participants. This Phase 1 trial was completed, enrolled 26 participants, and was conducted in the United States. It was a controlled, randomized study without double-blinding.
Yes, LY2886721 in a Capsule is another name for LY2886721 in a. The capsule refers to the dosage form evaluated in the Phase 1 trial NCT01775904. Both names refer to the same investigational small molecule developed by Eli Lilly and Company.